Search

Displaying results 4471 - 4480 of 10000 in total
  1. Drug

    3,4-Dihydroxybenzoic Acid

    go.drugbank.com/drugs/DB03946
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Oxidronic acid

    go.drugbank.com/drugs/DB14159
    Approved

  3. Drug

    PPI-1019

    go.drugbank.com/drugs/DB05832
    Investigational

    Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

  4. Drug

    ISIS 113715

    go.drugbank.com/drugs/DB05506
    Investigational

    In early trials, ISIS 113715 induced statistically significant improvements in multiple measures of glucose control along with statistically significant reductions in LDL-cholesterol. … ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes.

  5. Drug

    Motexafin lutetium

    go.drugbank.com/drugs/DB05296
    Investigational

    Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. … Motexafin lutetium is a pentadentate aromatic metallotexaphyrin with photosensitizing properties.

  6. Drug

    Mefenamic acid

    go.drugbank.com/drugs/DB00784
    Approved

    It is an inhibitor of cyclooxygenase.

    Synonyms: N-2,3-xylylanthranilic acid, N-(2,3-xylyl)-2-aminobenzoic acid
  7. Drug

    Dovitinib

    go.drugbank.com/drugs/DB05928
    Investigational

    Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. … Chiron currently has three ongoing Phase I clinical trials for dovitinib.

  8. Drug

    Latiglutenase

    go.drugbank.com/drugs/DB06326
    Investigational

  9. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in vitro. … PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).

  10. Drug

    Tesmilifene

    go.drugbank.com/drugs/DB04905
    Investigational

    Tesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected and very large survival advantage over doxorubicin alone in a randomized trial in advanced breast

    Synonyms: N,N-diethyl-2-((4-phenylmethyl)phenoxy)ethanamine